The Sjögren’s Foundation hosted the 5th Annual State of Sjögren’s, a professional education event designed to support healthcare providers who care for people living with Sjögren’s disease and to engage researchers advancing the understanding of the disease. While the program is created for clinicians, its ultimate purpose is to improve care, understanding, and outcomes for the Sjögren’s community.
This year’s State of Sjögren’s focused on the future of Sjögren’s treatments, featuring expert-led discussions on therapies currently in Phase 3 U.S. clinical trials. Speakers explored how these investigational treatments work in the body, where they are in the research process, and what progress may mean for patients over time.
The program featured presentations from leading Sjögren’s experts, including Sara McCoy, MD, Director of the UW Health Sjögren’s Clinic; Ghaith Noaiseh, MD, Associate Professor of Allergy, Clinical Immunology, and Rheumatology at KU Medical Center; and Alan Baer, MD, Director of the Jerome Greene Sjögren’s Clinic at Johns Hopkins University, who served as moderator.
Throughout the event, speakers shared insights into emerging treatment approaches, trends shaping future standards of care, and how ongoing research may one day lead to more targeted therapies for Sjögren’s disease. While there are currently no FDA-approved treatments specifically for Sjögren’s, discussions emphasized the growing momentum in research and the importance of continued clinical trials.
By educating healthcare professionals, the Foundation helps ensure that providers stay informed about the latest advances. This supports better conversations in the exam room and more informed, patient-centered care. Events like State of Sjögren’s reflect the Foundation’s commitment to progress, collaboration, and hope as research continues to move forward.
As research and education continue to advance, patients and caregivers can explore the Sjögren’s Foundation’s Treatment & Care resources for trusted information on current management and evolving treatment approaches.
The Sjögren’s Foundation hosted the 5th Annual State of Sjögren’s, a professional education event designed to support healthcare providers who care for people living with Sjögren’s disease and to engage researchers advancing the understanding of the disease. While the program is created for clinicians, its ultimate purpose is to improve care, understanding, and outcomes for the Sjögren’s community.
This year’s State of Sjögren’s focused on the future of Sjögren’s treatments, featuring expert-led discussions on therapies currently in Phase 3 U.S. clinical trials. Speakers explored how these investigational treatments work in the body, where they are in the research process, and what progress may mean for patients over time.
The program featured presentations from leading Sjögren’s experts, including Sara McCoy, MD, Director of the UW Health Sjögren’s Clinic; Ghaith Noaiseh, MD, Associate Professor of Allergy, Clinical Immunology, and Rheumatology at KU Medical Center; and Alan Baer, MD, Director of the Jerome Greene Sjögren’s Clinic at Johns Hopkins University, who served as moderator.
Throughout the event, speakers shared insights into emerging treatment approaches, trends shaping future standards of care, and how ongoing research may one day lead to more targeted therapies for Sjögren’s disease. While there are currently no FDA-approved treatments specifically for Sjögren’s, discussions emphasized the growing momentum in research and the importance of continued clinical trials.
By educating healthcare professionals, the Foundation helps ensure that providers stay informed about the latest advances. This supports better conversations in the exam room and more informed, patient-centered care. Events like State of Sjögren’s reflect the Foundation’s commitment to progress, collaboration, and hope as research continues to move forward.
As research and education continue to advance, patients and caregivers can explore the Sjögren’s Foundation’s Treatment & Care resources for trusted information on current management and evolving treatment approaches.